A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

• Published in: Atherosclerosis Vol. 314; pp. 33 - 40
• Main Authors: Harada-Shiba, Mariko, Ali, Shazia, Gipe, Daniel A., Gasparino, Evelyn, Son, Vladimir, Zhang, Yi, Pordy, Robert, Catapano, Alberico L.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.12.2020
• Subjects: Angiopoietin-like protein 3; Cardiovascular disease; Clinical trial; Evinacumab; Homozygous familial hypercholesterolemia; Lipids and lipoprotein metabolism; Cardiovascular disease; Clinical trial; Lipids and lipoprotein metabolism; Homozygous familial hypercholesterolemia; Angiopoietin-like protein 3; Evinacumab

Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial hypercholesterolemia. In this double-blind, placebo-controlled Phase 1 study, we compared safety, tolerability, ph...